# To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions

> **NCT00883064** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 32 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
- **DRUG:** Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)

## Key facts

- **NCT ID:** NCT00883064
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** 2000-04
- **Final completion:** 2000-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00883064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00883064, "To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00883064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*